Contract facts
FederalNo full NAICS 541714 intel page yet. Browse NAICS intelligence
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND EMERGING DISEASES PREPAREDNESS AND RESPONSE UNDER CONTRACT 75A50122D00002. is a federal award for Barda - Aspr / Daappo / Barda Dcma held by Glaxosmithkline LLC. Estimated value $91.1M ($18.2M obligated). Current period of performance ends Feb 21, 2027. Place of performance: DURHAM NC.
THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL COUNTERMEASURES (MCMS) FOR PANDEMIC INFLUENZA AND EMERGING DISEASES PREPAREDNESS AND RESPONSE UNDER CONTRACT 75A50122D00002.
Recompete timing
PublicCurrent PoP ends Feb 21, 2027 (143 days remaining). Agencies typically plan 12–18 months ahead — at 4.7 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 75A50124F61014? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordGlaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75A50124F61014?
75A50124F61014 (MCMS services) is a Barda - Aspr / Daappo / Barda Dcma award with a potential value of $91.1M, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75A50124F61014?
Barda - Aspr / Daappo / Barda Dcma awarded 75A50124F61014 to Glaxosmithkline LLC (potential $91.1M).
Who is the incumbent on 75A50124F61014?
Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Feb 21, 2027.
When does Glaxosmithkline LLC’s 75A50124F61014 come up for recompete?
SCOUT tracks a period-of-performance end of Feb 21, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 75A50124F61014? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.